

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Merck Sharp & Dohme LLC,
Petitioner,

v.

Halozyme Inc.,
Patent Owner.

Case No. PGR2025-00017
U.S. Patent No. 12,110,520

PETITIONER'S UPDATED EXHIBIT LIST

No.	Exhibit Description
1001	U.S. Patent No. 12,110,520
1002	File History of U.S. Patent No. 12,110,520
1003	Declaration of Dr. Michael Hecht
1004	Declaration of Dr. Sheldon Park
1005	U.S. Patent No. 7,767,429
1006	Chao et al., "Structure of Human Hyaluronidase-1, a Hyaluronan Hydrolyzing Enzyme Involved in Tumor Growth and Angiogenesis," <i>Biochemistry</i> , 46:6911-6920 (2007)
1007	WO 2010/077297, published 8 July 2010
1008	Stern et al., "The Hyaluronidases: Their Genomics, Structures, and Mechanisms of Action," <i>Chem. Rev.</i> 106:818-839 (2006)
1009	Jedrzejewski et al., "Structures of Vertebrate Hyaluronidases and Their Unique Enzymatic Mechanism of Hydrolysis," <i>Proteins: Structure, Function and Bioinformatics</i> , 61:227-238 (2005)
1010	Zhang et al., "Hyaluronidase Activity of Human Hyal1 Requires Active Site Acidic and Tyrosine Residues," <i>J. Biol. Chem.</i> , 284(14):9433-9442 (2009)
1011	Arming et al., "In vitro mutagenesis of PH-20 hyaluronidase from human sperm," <i>Eur. J. Biochem.</i> , 247:810-814 (1997)
1012	Bordoli et al., "Protein structure homology modeling using SWISS-MODEL workspace," <i>Nature Protocols</i> , 4(1):1-13 (2008)
1013	Frost, "Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration," <i>Expert Opinion on Drug Delivery</i> , 4(4):427-440 (2007)
1014	Brandon & Tooze, "Introduction to Protein Structure," Second Ed., Chapters 1-6, 11-12, 17-18 (1999)
1015	Table Associating Citations from the '520 Patent (EX1001) to Corresponding Citations in the '731 Application (EX1026)
1016	Steipe, "Consensus-Based Engineering of Protein Stability: From Intrabodies to Thermostable Enzymes," <i>Methods in Enzymology</i> , 388:176-186 (2004)

No.	Exhibit Description
1017	Green, "Computer Graphics, Homology Modeling, and Bioinformatics," <i>Protein Eng'g & Design</i> , Ch. 10, 223-237 (2010)
1018	Chica et al., "Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design," <i>Curr. Opin. Biotechnol.</i> , (4):378-384 (2005)
1019	Hardy et al., "Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20," <i>Reprod.</i> , 127:325-334 (2004)
1020	Pomering et al., "Restricted Entry of IgG into Male and Female Rabbit Reproductive Ducts Following Immunization with Recombinant Rabbit PH-20," <i>Am. J. Reprod. Immunol.</i> , (3):174-82 (2002)
1021	Baba et al., "Mouse Sperm Lacking Cell Surface Hyaluronidase PH-20 Can Pass through the Layer of Cumulus Cells and Fertilize the Egg," <i>J. Biol. Chem.</i> , 277(33):30310-4 (2002)
1022	Primakoff et al., "Reversible Contraceptive Effect of PH-20 Immunization in Male Guinea Pigs," <i>Biol Reprod.</i> , 56(5):1142-6 (1997)
1023	Tung et al., "Mechanism of Infertility in Male Guinea Pigs Immunized with Sperm PH-20," <i>Biol. Reprod.</i> , 56(5):1133-41 (1997)
1024	Rosengren et al., "Recombinant Human PH20: Baseline Analysis of the Reactive Antibody Prevalence in the General Population Using Healthy Subjects," <i>BioDrugs</i> , 32(1):83-89 (2018)
1025	U.S. Patent No. 9,447,401
1026	U.S. Patent Application No. 13/694,731
1027-1028	[Reserved]
1029	Gmachl et al., "The human sperm protein PH-20 has hyaluronidase activity," <i>FEBS Letters</i> , 3:545-548 (1993)
1030	Sills, "Retraction," <i>Science</i> , 319:569 (2008)
1031	Yue et al., "Loss of Protein Structure Stability as a Major Causative Factor in Monogenic Disease," <i>J. Mol. Biol.</i> , 353:459-473 (2005)

No.	Exhibit Description
1032	Wang & Moulton, "SNPs, Protein Structure, and Disease," <i>Hum. Mutation</i> , 17:263-270 (2001)
1033	Marković-Housley et al., "Crystal Structure of Hyaluronidase, a Major Allergen of Bee Venom," <i>Structure</i> , 8:1025-1035 (2000)
1034	"Negative Results," <i>Nature: Editorials</i> , 453:258 (2008)
1035	Lins et al., "Analysis of Accessible Surface of Residues in Proteins," <i>Protein Sci.</i> , 12:1406-1417 (2003)
1036	Hayden, "Chemistry: Designer Debacle," <i>Nature</i> , 453:275-278 (2008)
1037	Benkert et al., "Toward the Estimation of the Absolute Quality of Individual Protein Structure Models," <i>Bioinformatics</i> , 27:343-350 (2010)
1038	Schwede et al., "SWISS-MODEL: An Automated Protein Homology-Modeling Server," <i>Nucleic Acids Res.</i> , 31:3381-3385 (2003)
1039	Alberts, "Molecular Biology of the Cell," Fifth Edition, Chapter 3 (2007).
1040	He et al., "NMR Structures of Two Designed Proteins with High Sequence Identity but Different Fold and Function," <i>PNAS</i> , 105:14412-14417 (2008)
1041	Alexander et al., "A Minimal Sequence Code for Switching Protein Structure and Function," <i>PNAS</i> , 106:21149-21154 (2009)
1042	Ruan et al., "Design and Characterization of a Protein Fold Switching Network," <i>Nature Comm.</i> , 14 (2023)
1043	Sievers et al., "Fast, Scalable Generation of High-Quality Protein Multiple Sequence Alignments Using Clustal Omega," <i>Molecular Sys. Biology</i> , 7.1 (2011)
1044	Mihel, "PSAIA – Protein Structure and Interaction Analyzer," <i>BMC Structural Biology</i> , 8:21 (2008)
1045	Redline Comparison of the '731 and '520 Specifications
1046	Beasley & Hecht, "Protein Design: The Choice of <i>de Novo</i> Sequences," <i>J. Biological Chemistry</i> , 272:2031-2034 (1997)

No.	Exhibit Description
1047	Xiong et al., "Periodicity of Polar and Nonpolar Amino Acids is the Major Determinant of Secondary Structure in Self-Assembling Oligomeric Peptides," PNAS, 92: 6349-6353 (1995)
1048	Hayden, "Key Protein-Design Papers Challenged," Nature, 461:859 (2009)
1049	KEGG, <i>DRUG: Hyaluronidase (human recombinant)</i> , available at: https://www.genome.jp/entry/D06604
1050	Pace & Scholtz, "A Helix Propensity Scale Based on Experimental Studies of Peptides and Proteins," Biophysical J. 75:422-427 (1998)
1051	U.S. Patent Application No. 61/631,313
1052	U.S. Patent Application No. 61/796,208
1053	Hom_pre2011
1054	Hom_pre2011_header
1055	Hom_pre2011_header_clean
1056	Hom_pre2011.fasta
1057	Ph20_pre2011.aln-clustal_num
1058	Ph20_pre2011 Alignment html
1059	Leisola & Turunen, "Protein Engineering: Opportunities and Challenges," Appl. Microbiol. Biotechnol. 75:1225-1232 (2007)
1060	Hecht et al., "De Novo Proteins from Designed Combinatorial Libraries," Protein Sci., 13:1711-1723 (2004)
1061	Rosengren et al., "Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration," AAPS J., 17:1144-1156 (2015)
1062-1063	[Reserved]
1064	Collection of BLAST Webpages from the Internet Archive, navigable from: https://web.archive.org/web/20111022151531/http://www.clustal.org/omega/

No.	Exhibit Description
1065	Collection of Clustal Omega Webpages from the Internet Archive, navigable from: https://web.archive.org/web/20111022151531/http://www.clustal.org/omega/
1066	Collection of SWISS-MODEL Webpages from the Internet Archive, navigable from: https://web.archive.org/web/20110519141121/http://swissmodel.expasy.org/?pid=smh01&uid=&token=
1067	Collection of PyMol Webpages from the Internet Archive, navigable from: https://web.archive.org/web/20110701072314/http://pymol.org/
1068	Declaration of Jeffrey P. Kushan
1069	Swiss Model Printout of PH20 Model
1070	Swiss Model Printout of PH20 Model with E324D Mutation
1071	Swiss Model Printout of PH20 Model with E324N Mutation
1072	Swiss Model Printout of PH20 Model with E324R Mutation
1073	Swiss Model Printout of PH20 Model with E324A Mutation
1074	Swiss Model Printout of PH20 Model with E324H Mutation
1075	Swiss Model Printout of PH20 Model with E324S Mutation
1076	Declaration of Leif E. Peterson, II
1077-1081	[Reserved]
1082	United States District Court – National Judicial Caseload Profile, navigable from: https://www.uscourts.gov/data-news/reports/statistical-reports/federal-court-management-statistics/federal-court-management-statistics-december-2024
1083	Table Showing Outcomes of Disputed Motions to Stay Pending IPRs in DNJ
1084	News Release: “Halozyne Raises 2025 Financial Guidance Ranges and Reports Strong First Quarter 2025 Results,” navigable from: https://www.prnewswire.com/news-releases/halozyne-raises-2025-financial-guidance-ranges-and-reports-strong-first-quarter-2025-results-302447541.html

No.	Exhibit Description
1085	News Release: “Merck Breaks Ground on New \$1 Billion Biologics Center of Excellence in Wilmington, Delaware,” navigable from: https://www.merck.com/news/merck-breaks-ground-on-new-1-billion-biologics-center-of-excellence-in-wilmington-delaware/
1086	Halozyne Therapeutics, Inc. Q1 2025 Earnings Call Transcript (May 6, 2025)
1087-1112	[Reserved]
1113	Declaration of Sue Wang
1114	Declaration of Brian M. Goldberg
1115	Declaration of Katherine A. Helm
1116-1163	[Reserved]
1164	MERCK_PGR00355 - PTAB-PGR2021-00036-1 Merck-Genentech PGR
1165	MERCK_PGR00458 - PTAB-PGR2021-00036-16 Merck-Genentech PGR
1166	MERCK_PGR00462 - RE_2_25-cv-03179-ES-JRA_ HALOZYME, INC. v. MERCK SHARP & DOHME CORP.
1167	MERCK_PGR00094 - DNJ-2-25-cv-03179 Stipulation to Substitute Parties
1168	MERCK_PGR00090 - DNJ-2-25-cv-03179 2025-07-14 [019] Corporate Disclosure Statement
1169-1223	[Reserved]
1224 [NEW]	Declaration of Kelly Grez – Protective Order Material
1225-1233	[Reserved]
1234	MSD Netherlands Capital B.V., Preliminary Prospectus Supplement (May 14, 2024)
1235	Merck & Co., Inc., Form 8-K (Nov. 4, 2009)

No.	Exhibit Description
1236	Jennifer_Zachary WD_Redacted – Protective Order Material
1237	Merck & Co., Inc. Subsidiaries (Dec. 31, 2024)
1238	State of New Jersey, Certificate of Long Form Standing with Officers and Directors, Merck & Co., Inc. (Feb. 18, 2026)
1239	Press Release: “Merck and Schering-Plough to Merge” (Mar. 9, 2009)
1240	State of New Jersey, Certificate of Long Form Standing with Officers and Directors, Merck Sharp & Dohme LLC (Feb. 18, 2026)
1241	Company Statement: “Merck Sues Merck KGaA, Darmstadt, Germany for Improper Use of “Merck”” (Jan. 15, 2016)
1242	ZacharyJennifer ADP_Redacted – Protective Order Material
1243	Table Comparing the Boards of Directors for Merck & Co., Inc. and Merck Sharp & Dohme LLC
1244	Merck & Co., Inc., Form 851 – Affiliations Schedule for Tax Year Ending Dec. 31, 2024

Dated: March 12, 2026

Respectfully Submitted,

/Jeffrey P. Kushan/
Jeffrey P. Kushan
Reg. No. 43,401
Sidley Austin LLP
1501 K Street, N.W.
Washington, D.C. 20005

jkushan@sidley.com
(202) 736-8914
Attorney for Petitioner

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I hereby certify that on this 12th day of March, 2026, I caused to be served a true and correct copy of the foregoing and any accompanying exhibits by e-mail on the following counsel of record for Patent Owner:

Eldora L. Ellison, ellison-PTAB@sternekessler.com
R. Wilson Powers III, tpowers-PTAB@sternekessler.com
Jennifer Meyer Chagnon, jchagnon-PTAB@sternekessler.com
David H. Holman, dholman-PTAB@sternekessler.com
Tyler C. Liu, tliu-PTAB@sternekessler.com
David J. Kappos, dkappos@cravath.com
Aubrey Haddach, ahaddach@halozyme.com
Louis P. Panzica, Jr., lpanzica-PTAB@sternekessler.com
Joshua A. Mack, jmack@halozyme.com
Lauren N. Martin, laurenmartin@quinnemanuel.com
Mark H. Snyder, msnyder@halozyme.com
Pratibha Khanduri, pkhanduri-PTAB@sternekessler.com
Zachariah Summers, zachsummers@quinnemanuel.com
PTAB@sternekessler.com

Dated: March 12, 2026

Respectfully Submitted,

/Jeffrey P. Kushan/

Jeffrey P. Kushan
Reg. No. 43,401
Sidley Austin LLP
1501 K Street, N.W.
Washington, D.C. 20005
jkushan@sidley.com
(202) 736-8914
Attorney for Petitioner